Comparative Pharmacology
Head-to-head clinical analysis: SETHOTOPE versus TECHNETIUM TC 99M MEBROFENIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SETHOTOPE versus TECHNETIUM TC 99M MEBROFENIN.
SETHOTOPE vs TECHNETIUM TC-99M MEBROFENIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SETHOTOPE is a radiolabeled monoclonal antibody that binds to the prostate-specific membrane antigen (PSMA) on prostate cancer cells, delivering beta radiation (177Lu) to cause DNA damage and cell death.
Technetium Tc-99m mebrofenin is a radiopharmaceutical that, after intravenous administration, is taken up by hepatocytes and excreted into the biliary system. It allows scintigraphic imaging of the liver and biliary tract by emitting gamma rays detectable by a gamma camera.
1.0 mg IV every 12 hours for 7 days.
Adults: 1-5 mCi (37-185 MBq) IV bolus. Image immediately and at intervals up to 60 minutes for hepatobiliary scintigraphy.
None Documented
None Documented
Clinical Note
moderateTechnetium Tc-99m mebrofenin + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Technetium Tc-99m mebrofenin."
Clinical Note
moderateTechnetium Tc-99m mebrofenin + Eltrombopag
"The serum concentration of Eltrombopag can be increased when it is combined with Technetium Tc-99m mebrofenin."
Terminal elimination half-life: 12 hours (range 10-14 h); clinically, dosing interval is 12-24 h to maintain therapeutic levels
Terminal elimination half-life: approximately 6 hours (range 4-8 hours) in patients with normal hepatic function. In obstructive jaundice, half-life may be prolonged due to delayed biliary excretion.
Renal: 70% as unchanged drug; fecal: 25% as metabolites; biliary: 5%
Primarily biliary (hepatobiliary) excretion: ~75% of administered activity is excreted into bile and subsequently into feces within 24 hours. Renal excretion accounts for <10% of the administered dose.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical